文献速递膀胱癌与上尿路尿路上皮癌

根治性膀胱切除术后ctDNA检测不到的膀胱癌或可接受低强度影像监测:一项诊断准确性研究

Bladder Cancer with Undetectable Circulating Tumor DNA After Radical Cystectomy May Be Amenable to a Less Intense Imaging Surveillance Protocol: A Diagnostic Accuracy Study.
PubMed 文献 · Eur Urol Oncol · 2025-05-19

该单中心诊断准确性研究纳入94例接受机器人辅助根治性膀胱切除及前瞻性肿瘤知情ctDNA分析(Signatera™)的患者,以影像学为参考标准评估ctDNA检测复发的效能。中位随访16个月,ctDNA灵敏度与阴性预测值均为100.0%,特异度91.8%,阳性预测值84.5%。持续ctDNA检测不到的患者复发风险较低,或可受益于低强度监测方案。

要点

  • 根治性膀胱切除术后ctDNA检测复发灵敏度与NPV均达100.0%,特异度91.8%。
  • 持续ctDNA检测不到提示复发风险低,可考虑低强度影像监测。
  • 该策略需进一步研究验证临床效用后方可常规整合。

核心结论

  • 根治性膀胱切除术后ctDNA检测可作为膀胱癌监测的有价值工具。
  • 持续ctDNA检测不到的患者复发风险较低,或可受益于低强度监测方案。

研究设计与样本

  • 单中心诊断准确性研究,纳入2021至2023年接受机器人辅助根治性膀胱切除及前瞻性肿瘤知情ctDNA分析(Signatera™)的患者。
  • 共纳入94例,中位年龄70岁(IQR 63-77),75.4%为≥pT2疾病,71.3%为淋巴结阴性。
  • 排除非尿路上皮组织学或缺失ctDNA数据的患者,以影像学为参考标准评估ctDNA的患者水平诊断准确性。

主要发现

  • 中位随访16个月(IQR 9-22)期间,共进行388次影像学检查和283次ctDNA检测。
  • ctDNA灵敏度为100.0%(95%CI 100.0-100.0%),阴性预测值为100.0%(95%CI 100.0-100.0%)。
  • ctDNA特异度为91.8%(95%CI 87.6-95.5%),阳性预测值为84.5%(95%CI 76.8-91.3%)。

临床怎么用

  • 根治性膀胱切除术后可用ctDNA动态监测复发,持续检测不到者或可减少影像学检查强度。
  • ctDNA阳性者阳性预测值84.5%,应结合影像学进一步确认复发。

局限性

  • 单中心研究,样本量94例,中位随访仅16个月。
  • 需进一步研究验证ctDNA指导的低强度监测策略的临床效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Circulating tumor DNA (ctDNA) has shown promise as a prognostic biomarker for bladder cancer management. Current surveillance guidelines for patients with muscle-invasive bladder cancer recommend intense postoperative surveillance. Our aim was to assess the diagnostic performance of ctDNA in comparison to imaging studies for detection of disease recurrence after radical cystectomy. METHODS: We analyzed patients who underwent robot-assisted radical cystectomy and prospective tumor-informed ctDNA analysis (Signatera™) between 2021 and 2023 at a single institution. Patients with postoperative imaging and ctDNA results were included; patients with nonurothelial histology or missing ctDNA data were excluded. Diagnostic accuracy was evaluated at the patient level using imaging findings as the reference standard and ctDNA as the index test. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of ctDNA measurement were calculated. KEY FINDINGS AND LIMITATIONS: A total of 94 patients were included (median age 70 yr, interquartile range [IQR] 63-77). Most had ≥pT2 disease (75.4%) that was node-negative disease (71.3%). Over median follow-up of 16 mo (IQR 9-22), 388 imaging studies and 283 ctDNA tests were performed. ctDNA demonstrated sensitivity and an NPV of 100.0% (95% confidence interval [CI] 100.0-100.0%), specificity of 91.8% (95% CI 87.6-95.5%), and a PPV of 84.5% (95% CI 76.8-91.3%). CONCLUSIONS AND CLINICAL IMPLICATIONS: ctDNA measurement may serve as a valuable tool for bladder cancer surveillance after cystectomy. Patients with persistently undetectable ctDNA may benefit from less intensive surveillance protocols aligned with their lower risk of recurrence. This strategy warrants further research to validate its clinical utility and support integration into routine practice.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Eraky A, Ben-David R, Hug B, et al. Bladder Cancer with Undetectable Circulating Tumor DNA After Radical Cystectomy May Be Amenable to a Less Intense Imaging Surveillance Protocol: A Diagnostic Accuracy Study. Eur Urol Oncol. 2025. PMID: 40393820. doi:10.1016/j.euo.2025.04.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。